BioCentury | Nov 20, 2020
Deals

Mesoblast rebounds from FDA setback by landing Novartis as partner to develop mesenchymal stromal cells

Eight weeks after a complete response letter for remestemcel-L sent its share price tumbling, Mesoblast has unveiled a partnership with Novartis to develop the mesenchymal stromal cell product, starting with  acute respiratory distress syndrome, including ARDS associated with...
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

The recent failure of IFNβ in WHO’s master protocol trial for COVID-19 notwithstanding, there are plenty of reasons to suspect that interferons should be effective treatments for the infection. An analysis...
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

Casdin leads $65M round for AbSciProtein manufacturing company AbSci LLC said it raised $65 million in a series E round led by Casdin Capital. First-time backers Redmile Group and ArrowMark Partners joined returning investor Phoenix...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

Framework to allocate vaccinesA discussion draft of a framework on equitable allocation of COVID-19 vaccines released by The National Academies of Sciences, Engineering and Medicine proposes...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

As Gilead continues to expand its manufacturing capabilities for Veklury, the company has moved a step closer to gaining full approval of the therapy in the U.S. for COVID-19. The company announced its NDA submission for...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

This article has been updated to reflect that the Indian health ministry did not include Alzumab itolizumab among the drugs on its COVID-19 treatment protocol. With an Indian EUA for Alzumab, Biocon is now planning...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

A Phase III miss for a second IL-6 inhibitor in COVID-19 patients could be the death knell for the drug class in the disease. But the mortality benefit demonstrated by dexamethasone suggests a broader immunosuppressive...
BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19 develops severe disease gave a jolt to the biotech’s shares Monday, but more statistically robust data are still needed...
Items per page:
1 - 10 of 266